Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current Assets
Cash and cash equivalents	$ 13,471	$ 19,055
Prepaid expenses and other current assets	3,366	2,515
Total Current Assets	16,837	21,570
Property and equipment, net	859	905
Deposits and other assets	23	23
Total Assets	17,719	22,498
Current Liabilities:
Accounts payable	3,796	1,993
Accrued expenses	2,134	2,627
Warrant liabilities	9,731	14,821
Accrued employee benefits	787	313
Deferred rent	40	3
Total Current Liabilities	16,488	19,757
Long term deferred rent	470	492
Total Liabilities	16,958	20,249
Commitments and Contingencies
Stockholders’ Equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value; 250,000,000 shares authorized, 118,017,693 issued and 117,936,211 outstanding and 117,254,196 issued and 117,172,714 outstanding, respectively	118	117
Additional paid-in capital	177,331	175,762
Accumulated deficit	(174,880)	(172,034)
Total Synthetic Biologics, Inc. and Subsidiaries Equity	2,569	3,845
Non-controlling interest	(1,808)	(1,596)
Total Stockholders’ Equity	761	2,249
Total Liabilities and Stockholders' Equity	$ 17,719	$ 22,498